Dr. Petrylak on Trial of Atezolizumab in Urothelial Carcinoma

Daniel P. Petrylak, MD
Published: Friday, Feb 24, 2017



Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the updates of a study of atezolizumab in patients with metastatic urothelial carcinoma (mUC).

In this phase Ia study, patients with mUC who were previously treated with platinum-based chemotherapy received anti–PD-L1 therapy with atezolizumab at 15 mg/kg of 1200 mg intravenously every 3 weeks.

Long-term treatment with atezolizumab was well tolerated, showed durable responses, and extended overall survival by 27% (95% CI, 0.18-0.37).
 


Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the updates of a study of atezolizumab in patients with metastatic urothelial carcinoma (mUC).

In this phase Ia study, patients with mUC who were previously treated with platinum-based chemotherapy received anti–PD-L1 therapy with atezolizumab at 15 mg/kg of 1200 mg intravenously every 3 weeks.

Long-term treatment with atezolizumab was well tolerated, showed durable responses, and extended overall survival by 27% (95% CI, 0.18-0.37).
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x